Advance V116 pneumococcal conjugate vaccine to Phase 3 clinical trials
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Apr 2022
- Due
- 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“V116, which is expected to move to Phase 3 in 2022”
What we found
Evidence strength A What the grades mean
Merck confirmed in its 2022 10-K filing that V116 was in Phase 3 clinical development, indicating the commitment to advance the vaccine to Phase 3 by the end of 2022 was met.
-
A Merck & Co., Inc. 10-K filed 2023-02-24
“the Company currently has candidates in Phase 3 clinical development in several other therapeutic areas including: •V116, an investigational 21-valent pneumococcal conjugate vaccine” ✓ confirmed on the page
Market reaction: the shares moved -2.8% against the S&P 500 over the three sessions around the disclosure (23 Feb 2023 to 28 Feb 2023). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Advance
- Deliverable
- V116 pneumococcal conjugate vaccine
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Merck & Co., Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-MRK-004444 · Corrections policy